• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
3-Bromo-4-fluorobenzaldehyde
5-Methyl-1,3,4-oxadiazol2(3H)-one
4-Amino-6-methyl-3 oxo2,3, 4,5-tetrahydro 1.2.4-triazine hydrochloride
4-Acetylamino-6-methyl -3-oxo-2,3,4,5-tetrahydro-1,2,4-triazine
3-Pyridinecarboxaldehyde
Ethyl 3 Fluorobenzoate

Chinese Tycoon Eyes $500M IPO of Luye Life Sciences' Clinic Arm

biospaceJanuary 25, 2018

Tag: Luye Life Sciences , IPO

Luye Life Sciences Group, run by acquisitive Chinese entrepreneur Liu Dianbo, is considering a Singapore initial public offering of its health-care services arm that could raise as much as $500 million, people with knowledge of the matter said.

The company’s Luye Medical Group unit plans to evaluate proposals from investment banks as soon as next month, according to the people. The Singapore-based company aims to sell shares later this year, the people said, asking not to be identified as the discussions are private. 

Previous:NIH Gets Into CRISPR/Cas9, Launches $190M Genome Editing Research Program

Next:J&J to Spend More on R&D With Tax Reform Money

Related News

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

BioPharmaSpec, the leading global Contract Research Organization (CRO) for Discovery and Preclinical Characterization of Biopharmaceuticals, has officially announced three new European facilities.

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Chinese Tycoon Eyes $500M IPO of Luye Life Sciences' Clinic Arm | Pharmasources.com

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

PharmaSourcesNovember 15, 2024

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

You may like
More>>

Sodium Tripolyphosphate

Sodium Tripolyphosphate
171500-79-1 lipoglycopeptide antibiotic Dalbavancin

171500-79-1 lipoglycopeptide antibiotic Dalbavancin
Calcipotriene

Calcipotriene
Membrane extruder/Liposomes extruder/

Membrane extruder/Liposomes extruder/
STPP(Sodium Tripolyphosphate)

STPP(Sodium Tripolyphosphate)
dipotassium glycyrrhizinate

dipotassium glycyrrhizinate
R-(+)- Alpha Lipoic Acid (RALA)

R-(+)- Alpha Lipoic Acid (RALA)
High purity nutritional supplement R-lipoic acid powder

High purity nutritional supplement R-lipoic acid powder
R-(+)-Lipoic Acid

R-(+)-Lipoic Acid
24-carbonyl-1,3-bi-TBS-trans- Calcipotriol

24-carbonyl-1,3-bi-TBS-trans- Calcipotriol

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service